Quarterly report pursuant to Section 13 or 15(d) Related Documents EX-31.1 EX-31.2 EX-32.1 EX-32.2
(WorldNews Asia)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q â˜`QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or â˜� TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000- 55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 45-5401931 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 880 Third Avenue, 12th Floor New York, NY 10022 (Address of...